Barclays set a $40.00 price target on Pfizer (NYSE:PFE) in a report issued on Friday. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently commented on PFE. Zacks Investment Research downgraded shares of Pfizer from a buy rating to a hold rating in a research note on Sunday, July 15th. Morningstar set a $46.00 target price on shares of Pfizer and gave the stock a neutral rating in a research note on Tuesday, October 9th. BMO Capital Markets restated a buy rating and issued a $42.00 target price on shares of Pfizer in a research note on Thursday, July 19th. Jefferies Financial Group restated a neutral rating and issued a $39.00 target price on shares of Pfizer in a research note on Monday, July 9th. Finally, Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the stock a buy rating in a research note on Thursday, October 4th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $42.80.

NYSE:PFE traded up $0.50 during mid-day trading on Friday, hitting $44.50. 18,236,118 shares of the stock traded hands, compared to its average volume of 21,913,520. The company has a market capitalization of $261.93 billion, a price-to-earnings ratio of 16.79, a PEG ratio of 2.25 and a beta of 0.96. Pfizer has a 52 week low of $33.20 and a 52 week high of $45.81. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.74 by $0.07. The company had revenue of $13.47 billion for the quarter, compared to the consensus estimate of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 EPS. As a group, equities analysts forecast that Pfizer will post 2.99 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.06%. Pfizer’s dividend payout ratio is presently 51.32%.

In other Pfizer news, major shareholder Pfizer Inc acquired 55,556 shares of the company’s stock in a transaction dated Monday, October 15th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the purchase, the insider now owns 21,976,484 shares in the company, valued at $395,576,712. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Loretta V. Cangialosi sold 26,814 shares of the stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $40.16, for a total transaction of $1,076,850.24. Following the transaction, the vice president now owns 102,360 shares in the company, valued at $4,110,777.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 234,096 shares of company stock worth $9,366,617. Insiders own 0.06% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ballew Advisors Inc purchased a new stake in Pfizer during the first quarter valued at approximately $102,000. Fort L.P. purchased a new position in shares of Pfizer in the second quarter worth $121,000. Selective Wealth Management purchased a new position in shares of Pfizer in the third quarter worth $155,000. W.G. Shaheen & Associates DBA Whitney & Co purchased a new position in shares of Pfizer in the first quarter worth $132,000. Finally, Braun Bostich & Associates Inc. purchased a new position in shares of Pfizer in the first quarter worth $139,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Further Reading: Insider Trading

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.